postprandial

1-Deoxynojirimycin (Moranoline) is a potent α-glucosidase inhibitor, suppressing postprandial blood glucose, thereby possibly preventing diabetes mellitus.

1-Deoxynojirimycin hydrochloride (Moranoline) is a potent and selective inhibitor of alpha-glucosidase, most commonly found in mulberry leaves. Duvoglustat is used to suppress the elevation of postprandial hyperglycemia.

ARRY-403 is a novel glucokinase activator that reduces fasting and postprandial blood glucose in patients with type 2 diabetes.

Casein is a milk protein with multiple roles in a novel drug delivery system that affects postprandial amino acid delivery in different ways through its intragastric coagulation properties.

AZD7687 is a potent and selective DGAT1 inhibitor with an IC50 value of 80 nM (hDGAT1). IC50 value: 80 nM [1] Target: DGAT1 in vitro: Plasma AZD7687 exposure was measured repeatedly. AZD7687 markedly reduced postprandial TAG excursion with a steep concent

Mizagliflozin is an orally active, selective SGLT1 inhibitor with a Ki value of 27 nM for human SGLT1. Mizagliflozin is 303 times more selective for SGLT1 than for SGLT2. Mizagliflozin is an anti-diabetic drug that can improve postprandial blood sugar fluctuations and may have the potential to improve chronic constipation.

α-glucosidase/PTP1B-IN-1 (compound 8a) is an effective inhibitor of both α-glucosidase and PTP1B, with IC50 values of 66.3 μM and 47.0 μM, respectively. It also exhibits strong inhibitory activity against α-amylase, having an IC50 of 30.62 μM. This compound is capable of binding to the active sites of α-glucosidase and PTP1B. α-glucosidase/PTP1B-IN-1 holds potential for reducing postprandial blood glucose levels and may be useful in managing type 2 diabetes.

Cetagliptin is an orally active inhibitor of dipeptidyl peptidase 4 (DPP-4) and CYP2D6, with an IC50 of 6 µM. It acts as a substrate for P-glycoprotein and helps reduce GLP-1 degradation, maintaining postprandial blood glucose levels. It is used in research for type 2 diabetes.

Resinacein L is an inhibitor of α-glucosidase with an IC50 of 0.635 mM. This compound can slow the digestion and absorption of carbohydrates, thereby reducing postprandial blood glucose levels.

α-Glucosidase-IN-88 (Compound 3K) is an orally active and potent α-glucosidase inhibitor with an IC50 value of 6.40 µM. It reduces postprandial blood glucose levels by inhibiting the hydrolysis of carbohydrates, preventing the enzyme from breaking glycosidic bonds. α-Glucosidase-IN-88 shows potential for research in type 2 diabetes mellitus (T2DM).

α-Glucosidase-IN-43 (compound AS14) is an α-glucosidase inhibitor with an IC50 of 4.32 μM, demonstrating acute blood-glucose-lowering properties. It is safe and effective in vivo, showing no toxicity to normal fibroblasts in mice and can ameliorate diabetes induced by streptozotocin in rats. α-Glucosidase-IN-43 is applicable for research on postprandial hyperglycemia in diabetic patients.

α-Glucosidase-IN-92 (compound 14b) is a non-competitive inhibitor targeting α-glucosidase with an IC50 of 64.0 μM, displaying greater inhibitory potency than Acarbose (IC50=750 μM). It has excellent oral bioavailability and can cross the blood-brain barrier. This compound slows carbohydrate hydrolysis and reduces postprandial blood glucose levels, making it useful for antidiabetic studies in type 2 diabetes.

Enprostil is a synthetic PGE2 analog that has an inhibitory effect on gastric acid secretion, a mucoprotective effect, and a postprandial lowering effect on gastrin. It has efficient and safe in the therapy of gastroduodenal ulcers.

AZD-6370 is a glucokinase activator. AZD-6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food. AZD-6370 do not affect the central counterregulatory response to hypoglycemia

WB403 is a TGR5 activator. WB403 significantly decreases fasting blood glucose, postprandial blood glucose and HbA1c, improves glucose tolerance in type 2 diabetic mice. WB403 increases pancreatic β-cells and restores the normal distribution pattern of α-

50F10 is a stabilizer for the active LPL dimer. It can act by preventing angptl4- and heat-induced inactivation of LPL and reducing postprandial triglyceride levels.

Trilobatin (P-Phlorizin) has anti-oxidant effect, can increase superoxide dismutase (SOD) activity.Trilobatin has anti-inflammatory effect, it potentially inhibits the lipopolysaccharide (LPS)-induced inflammatory response by suppressing the NF-κB signaling pathway.Trilobatin shows a strong inhibitory activity against α-glucosidase and a moderate inhibitory activity against α-amylase for management of postprandial hyperglycemia with less side effect.

Arbaclofen placarbil( XP19986) is a GABA(B) receptor agonist.Arbaclofen Placarbil is a novel R-baclofen prodrug with improved absorption, distribution, metabolism, and elimination properties compared to R-baclofen. And it can reduce postprandial reflux in

Massarigenin C is a fungal metabolite that has been found inM. flavoroseaand has enzyme inhibitory activities.1,2Massarigenin C inhibits neuraminidasein vitro(IC50= 4.15 μM).2It is also an inhibitor of yeast α-glucosidase (IC50= 1.25 mM).1It reduces the postprandial peak in blood glucose levels in an oral sucrose tolerance test in normo- and hyperglycemic mice when administered at doses of 3.2, 10, and 31.6 mg/kg.

Saxagliptin is a new oral hypoglycemic of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Saxagliptin is a competitive DPP4 inhibitor that slows the inactivation of the incretin hormones and reducing fasting and postprandial glucose conce

(+/-)- Adomeglivant, also known as LY2409021, is a potent and selective glucagon receptor antagonist. LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Blockade of glucagon signalling in patients with type 2 diabetes is well tolerated and results in substantial reduction of fasting and postprandial glucose with minimal hypoglycaemia, but with reversible increases in aminotransferases. Inhibition of glucagon signalling by LY2409021 is a promising potential treatment for patients with type 2 diabetes and should be evaluated in longer clinical trials to better evaluate benefits and risks.

D-(+)-Sorbose, the active enantiomer of D-Sorbose, inhibits disaccharidase activity and demonstrates suppressive effects on postprandial blood glucose and insulin levels in rats. Its role as a sweetener may aid in preventing lifestyle-related diseases, such as type 2 diabetes mellitus.

GIP (1-30) amide, human acetate is a fragment of glucose-dependent insulinotropic polypeptide (GIP), an incretin hormone that plays a crucial role in stimulating insulin secretion and mitigating postprandial glycemic excursions. This compound has been shown to enhance insulin secretion in a dose-dependent manner across concentrations of 10^-9 to 10^-6 M [1].

Stevisalioside A (Compound 2), isolated from the roots of Stevia serrata, is an orally active antidiabetic agent that inhibits Protein Tyrosine Phosphatase 1B (PTP1B) with an IC50 value of 526.8 μM. It effectively lowers blood glucose levels and attenuates the postprandial peak observed in oral glucose and insulin tolerance tests in Streptozotocin-induced hyperglycemic mice [1].